The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
about
Metabolic signals in sleep regulation: recent insightsAltered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?Effect of maternal body mass index on hormones in breast milk: a systematic reviewDevelopment of minimally invasive techniques for management of medically-complicated obesityBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingThe intestinal microbiome in early life: health and diseaseGLP-1 based therapeutics: simultaneously combating T2DM and obesity.Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2.Significant obesity-associated gene expression changes occur in the stomach but not intestines in obese mice.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Acute exercise and hormones related to appetite regulation: a meta-analysis.Peripheral targets in obesity treatment: a comprehensive update.Gastrointestinal hormones and polycystic ovary syndrome.Targeting cellular drivers and counter-regulators of hyperglycaemia- and transforming growth factor-β1-associated profibrotic responses in diabetic kidney disease.Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.Liraglutide: a review of its use in the management of obesity.Liraglutide for Type 2 diabetes and obesity: a 2015 update.Is there any interplay between incretins and bile acids? What is the role of bariatric surgery?Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations.Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.Weight Loss and Appetite Control in Women.Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese SubjectsType 2 diabetes mellitus
P2860
Q26770483-EE313814-C316-4B24-8F95-6AF63C377095Q26779389-9290CCFC-0398-4D46-8871-0F08C194B7B5Q26824868-FFD3A951-41DD-422E-BD44-1CBE88077370Q26851369-1091F545-CEEA-41A8-9DEB-F8FD32510D93Q26992979-6538608A-30C2-45AC-AC86-010CE27DD603Q26996343-E3A536B3-EB6E-4FFE-AB5A-37FD03FA20CDQ35200252-36EB0C1B-C783-46C5-8810-F4FD922D537FQ35209811-27714770-21B7-46B0-9F7E-6D51AAAE7457Q36187926-1548D647-5B71-4D4B-B5E2-360951829646Q36949405-3954E57C-33F0-4CC3-83EA-5D1502E71461Q37340223-AC96D42B-0320-416C-9604-CAF7B03B114AQ38156716-D2DAE980-D9AD-42B0-A96A-62A483546345Q38194649-DACDEB3A-FCD3-477B-8316-611786CFC189Q38208929-824A1B2B-33BA-4DAA-A147-E800B830004FQ38236212-1D106C65-50F0-4464-A1E6-ADEB1D0274F4Q38254745-6C3E9B49-27E0-46E7-A728-AB79D260A9D2Q38488650-9B90627B-2F07-4575-8EE7-52BD7FA5FBFBQ38536672-15F08BE7-2138-4B07-B6A9-2E900C4AAD0CQ38623207-38DA5D86-7CEC-4646-BA57-3BF6A54C73DCQ38634679-9ECF5229-6BE6-453C-9369-45D5890ADB72Q38708352-498AF8FF-6AAE-4224-B4FC-645569473D52Q40572806-7339792F-3819-40A3-962C-F1B211B2180FQ42004480-733EC1D6-4BCF-4BBE-BEA7-5BD5CCD5FF6DQ47197078-55DA6469-7086-4220-A1A0-62DF86B9165FQ47252691-283202F2-0B4E-49C9-90C4-F765B338A520Q47568761-D3DCB528-6CC1-4CAD-827D-82BC069AC81DQ51312581-497610F2-9B84-4C9A-930E-FA1E051C887EQ58447117-5673018B-F7A5-4C3F-BB55-332446201ED2Q58447602-115AF4D8-BBF7-4AAC-A97D-B35BA3B5C962
P2860
The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of glucagon-like pept ...... tial therapeutic implications.
@en
type
label
The role of glucagon-like pept ...... tial therapeutic implications.
@en
prefLabel
The role of glucagon-like pept ...... tial therapeutic implications.
@en
P2860
P356
P1476
The role of glucagon-like pept ...... tial therapeutic implications.
@en
P2860
P356
10.1111/DOM.12119
P50
P577
2013-05-26T00:00:00Z